Lineage Cell Therapeutics
LCTX
LCTX
110 hedge funds and large institutions have $112M invested in Lineage Cell Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 39 reducing their positions, and 25 closing their positions.
Holders
110
Holders Change
-14
Holders Change %
-11.29%
% of All Funds
1.74%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
12
Increased
20
Reduced
39
Closed
25
Calls
$389K
Puts
$117K
Net Calls
+$272K
Net Calls Change
-$1.05M
Top Buyers
| 1 |
BC
1
Broadwood Capital
New York
|
$53.8M |
| 2 |
RA
2
Raffles Associates
New York
|
$2.01M |
| 3 |
3
JPMorgan Chase & Co
New York
|
$2.85M |
| 4 |
4
Nuveen Asset Management
Chicago,
Illinois
|
$750K |
| 5 |
AC
5
Aristides Capital
Louisville,
Kentucky
|
$154K |
